<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> (TZDs) are frequently used pharmacotherapeutics for <z:hpo ids='HP_0005978'>type II diabetes mellitus</z:hpo>, which exert their effect through peroxisomal proliferator <z:chebi fb="4" ids="48705">agonist</z:chebi> receptor (PPAR) mediated <z:mp ids='MP_0002891'>increased insulin sensitivity</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>TZDs are known to cause marrow suppression and to stimulate adipogenesis </plain></SENT>
<SENT sid="2" pm="."><plain>Case and cohort studies show TZDs worsen thyroid-associated orbitopathy </plain></SENT>
<SENT sid="3" pm="."><plain>We present a case consistent with earlier reports of marrow suppressive <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> manifesting as <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, a new implication of hypoerythropoetinemia, and non-Graves'-associated proliferative <z:hpo ids='HP_0000520'>proptosis</z:hpo> </plain></SENT>
</text></document>